Technology | Cath Lab | April 15, 2019

Biotronik Begins U.S. Launch of PK Papyrus Covered Coronary Stent

Offers a lifesaving solution for the treatment of acute coronary artery perforations

BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.

April 15, 2019 — Biotronik began its U.S. commercial launch of the PK Papyrus covered coronary stent system for use in the emergency treatment of acute coronary perforations.[1,2]

Now available in the United States, the PK Papyrus is the first FDA-approved device for the treatment of acute perforations in nearly two decades. More than 800,000 percutaneous coronary intervention (PCI) procedures are performed annually in the U.S. and fewer than 8,000 require a covered stent, classifying PK Papyrus as a Humanitarian Use Device.[3] 

The ultrathin strut, single-stent design and unique electrospun polyurethane membrane expands treatment options and is designed to reduce the high rate of adverse outcomes associated with coronary artery perforations.

It is available in 17 sizes and is the only 5 French compatible covered coronary stent on the U.S. market.[4] Biotronik's covered stent is 58 percent more flexible, and has a 23 percent smaller crossing profile compared to Graftmaster, which has a layered dual-stent design and is the only other covered coronary stent available in the U.S.[5,6]

For more information: www.PKPapyrus.com 

References: 
1. Humanitarian Device. Authorized by Federal law for use in the treatment of acute perforations of native coronary arteries and coronary bypass grafts in vessels 2.5 to 5 mm in diameter. The effectiveness of this device for this use has not been demonstrated.
2. Institutional Review Board approval is required for use.
3. Decision Resources Group, Medtech 360, Interventional Cardiology Devices Market Analysis, US 2017.
4. 5F compatible for ø 2.5-4.0 mm.
5. Compared to Jostent Graftmaster 3.0/16 (BIOTRONIK data on file).
6. Compared to Graftmaster 2.8/16 (BIOTRONIK data on file).

Related Content

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Overlay Init